| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -4.7 | -7.7 |
| EPS (diluted, $ a share) | $-1.47 | $-2.44 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: PASG. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Passage BIO, Inc.: key numbers
- Share price
- $4.13Close, Nov 16
- Market cap
- $13.3M
- Shares outstanding
- 3.22MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Passage BIO, Inc.
All →Passage BIO Stock Plan Amendment
Passage Bio stockholders approved the 2026 Equity Incentive Plan at a special meeting, which will become effective upon the completion of the company's merger with Remix Therapeutics. The plan reserves 5,772,500 shares for issuance and is intended to replace existing equity incentive plans from both companies. The plan also includes an evergreen provision for annual share increases through 2036.
- Counterparty
- Remix Therapeutics, Inc.